Although CDK inhibitors are not approved for RA and are currently under pre-clinical investigation, there is potential that CDK4/6 inhibitors may be more relevant to RA individuals with the myeloid pathotype given its enrichment in this study. Here, CDK4 is linked to rheumatoid arthritis.